The Workshop

Pre-conference workshop
Biosimilars – evolution or revolution for the pharmaceuticals market
Date:	Tuesday 17 February 2009
Led by:	Jo Pisani Partner Pharmaceuticals Market & Value Advisory PRICEWATERHOUSECOOPERS
About the workshop:
Biologics have outperformed the pharmaceutical market as since they address areas of clinical need that are unmanageable with conventional therapeutics and they command a premium price. Consequently one would expect biosimilars to be commercially attractive. However, we have seen very few companies enter this field and for those who have they have been limited to the “easier” products to launch. This half-day workshop will examine the challenges to be addressed and identify strategies to enter this potentially lucrative market.
Workshop agenda
09:30	Registration and coffee
10:00	Session 1: Exploring the biosimilars opportunity
10:45	Morning refreshments
11:15	Session 2: Exploring obstacles to entry such as regulatory hurdles, strategic obstacles, pricing obstacles, sales & marketing obstacles
12:00	Session 3: Identifying potential players and business models
12:30	Lunch
13:30	Session 4: Exploring decision making tools
14:15	Close of workshop
About your workshop leader:
Jo Pisani	is a Partner in the Pharmaceuticals Advisory team of PricewaterhouseCoopers. She has thirteen years of industry experience in the pharmaceuticals, energy, petrochemicals and fast-moving consumer goods industries with BP and SmithKline Beecham where she held positions in the engineering, operations, IT and commercial functions. Before joining PwC, she spent three years with Booz Allen Hamilton, a strategic management consultancy where she focused on strategic issues in the pharmaceuticals and energy sectors. Her focus is providing advice to her clients in the areas of strategy, evaluations and due diligence. Her clients include pharmaceutical companies, generic companies, biotech companies, contract manufacturers and financial institutions.
PriceWaterhouseCoopers	has extensive experience working with organisations across the industry, including: proprietary and generic drug manufacturers, specialty drug makers, medical device and diagnostics suppliers, biotechnology companies, wholesalers, pharmacy benefit managers, contract research organisations, and industry associations. We have made a deep commitment to understanding the forces affecting our clients’ operations and have aligned our practice with the market to ensure that our people are deeply knowledgeable about the relationships that suppliers have with providers, payers, regulators and patients. Whether you are an emerging company seeking venture capital to fund research or advice on a collaboration to commercialize a product, or an established company looking to improve or expand operations, you can count on our insight and experience to find the best approaches to achieve your financial, operational and strategic objectives. www.pwc.com/pharma